$\mathrm{C} 6-\mathrm{O} 4$
$\mathrm{C} 7-\mathrm{O} 1$
$\mathrm{C} 6-\mathrm{C} 1-\mathrm{C} 2$
$\mathrm{C} 6-\mathrm{C} 1-\mathrm{C} 7$
$\mathrm{C} 2-\mathrm{C} 1-\mathrm{C} 7$
$\mathrm{O} 3-\mathrm{C} 2-\mathrm{C} 3$
$\mathrm{O} 3-\mathrm{C} 2-\mathrm{C} 1$
$\mathrm{C} 3-\mathrm{C} 2-\mathrm{C} 1$
$\mathrm{C} 4-\mathrm{C} 3-\mathrm{C} 2$
$\mathrm{C} 3-\mathrm{C} 4-\mathrm{C} 5$
$\mathrm{C} 4-\mathrm{C} 5-\mathrm{C} 6$
$\mathrm{O} 4-\mathrm{C} 6-\mathrm{C} 5$
$\mathrm{O} 4-\mathrm{C}-\mathrm{C} 1$
$\mathrm{C} 5-\mathrm{C}-\mathrm{C} 1$
$\mathrm{O} 1-\mathrm{C}-\mathrm{O} 2$

1.04 (3)
0.97 (3)
119.20 (14)
118.3 (2)
121.3 (2)
120.2 (2)
118.6 (2)
120.5 (2)
119.2 (2)
120.2 (2)
100.5 (14)
103.4 (16)
120.2 (15)
118.4 (15)

References
Dega-Szafran, Z., Gdaniec, M., Grunwald-Wyspianska, M., Kosturkiewicz, Z., Koput, J., Krzyzanowski, P. \& Szafran, M. (1992). J. Mol. Struct. 270, 99-124.

Golubev, N. S. \& Denisov, G. S. (1992). J. Mol. Struct. 272, 263-276.
Jeffrey, G. A. \& Saenger, W. (1991). Hydrogen Bonding in Biological Structures. Berlin, Heidelberg: Springer-Verlag.
Kuma (1991). Kuma KM-4 User's Guide. Version 3.2. Kuma Diffraction, Wroclaw, Poland.
Sheldrick, G. M. (1990). Acta Cryst. A46, 467-473.
Sheldrick, G. M. (1994). J. Appl. Cryst. In preparation.
Siemens (1989). Stereochemical Workstation Operation Manual. Release 3.4. Siemens Analytical X-ray Instruments Inc., Madison, Wisconsin, USA.

Table 3. Hydrogen-bonding geometry ( $\AA{ }^{\circ}{ }^{\circ}$ )

| $D-\mathrm{H} \cdots \mathrm{A}$ | D-H | H $\cdots$ A | D . A | $D-\mathrm{H} \cdots A$ |
| :---: | :---: | :---: | :---: | :---: |
| (I) |  |  |  |  |
| O3-H3O $\cdots \mathrm{O}$ | 0.93 (4) | 1.74 (4) | 2.596 (3) | 152 |
| O2-H2O . O 4 | 0.89 (4) | 1.68 (4) | 2.522 (3) | 156 |
| O4-H4O $\mathrm{OSO}^{\text {i }}$ | 0.76 (3) | 1.95 (3) | 2.683 (3) | 161 |
| (II) |  |  |  |  |
| O1-H1O . . O 3 | 1.14 (14) | 1.57 (13) | 2.540 (3) | 139 (10) |
| O3-H3OB...O1 | 1.06 (10) | 1.61 (11) | 2.540 (3) | 143 (8) |
| O3-H3OA. ${ }^{\text {O }}$ O1W | 0.71 (7) | 2.03 (7) | 2.705 (4) | 159 (6) |
| $\mathrm{O} 1 W-\mathrm{H} 1 W . . \mathrm{O} 3$ | 0.85 (10) | 1.92 (11) | 2.705 (4) | 152 (10) |
| $\mathrm{O} 1 W-\mathrm{H} 2 W \cdots \mathrm{O} 1^{\text {ii }}$ | 0.88 (10) | 2.33 (9) | 3.069 (6) | 143 (5) |
| (III) |  |  |  |  |
| O3- $\mathrm{H} 3 \mathrm{O} \cdots \mathrm{O} 1$ | 1.08 (3) | 1.46 (3) | 2.497 (2) | 158 (2) |
| O4- $\mathrm{H} 4 \mathrm{O} \cdots \mathrm{O}$ | 1.04 (3) | 1.59 (3) | 2.556 (2) | 152 (3) |
| N1'-H1N...O2 | 0.97 (3) | 1.73 (3) | 2.692 (2) | 175 (2) |
| $\mathrm{C} 2^{\prime}-\mathrm{H}^{\prime}{ }^{\prime} \ldots$. O 1 | 0.93 (2) | 2.50 (2) | 3.211 (3) | 133 (2) |
| Symmetry codes: (i) $\frac{1}{2}-x, y-\frac{1}{2}, \frac{1}{2}+z$; (ii) $\frac{3}{2}-x, \frac{1}{2}+y, z-\frac{1}{2}$. |  |  |  |  |

The $\gamma$-resorcylic acid molecule in (II) lies on a mirror plane through $\mathrm{C} 7, \mathrm{C} 1$ and C 4 , therefore the carboxyl and phenolic OH groups are disordered. The molecule adopts two overlapping orientations related by the mirror plane. The positions of all H atoms except for $\mathrm{H} 1 W$ were determined from a $\Delta F$ map. H 1 O and $\mathrm{H} 3 \mathrm{O} B$ were identified as a broad peak between O1 and O3, which was probably the superposition of the electron densities of these two closely situated H atoms, and were both given a site occupancy of 0.5 and refined. The position of $\mathrm{H} 1 W$ was calculated assuming hydrogen-bond formation with $O(3)$ and refined.

Data collection, cell refinement, and data reduction: Kuma KM-4 software (Kuma, 1991). Program(s) used to solve structure: SHELXS86 (Sheldrick, 1990). Program(s) used to refine structure: SHELXL93 (Sheldrick, 1994). Molecular graphics: Stereochemical Workstation (Siemens, 1989). Software used to prepare material for publication: SHELXL93.

The authors wish to thank Professor M. Jaskolski for helpful discussions. Financial support from the Committee of Scientific Research (Poland) and from the Russian Foundation of Fundamental Research (Project 93-03-5664) is gratefully acknowledged.

[^0]Acta Cryst. (1994). C50, 1626-1629
$3^{\prime}$-Azido- ${ }^{\prime}, 3^{\prime}$ '-dideoxy-5-hydroxymethyluridine

Jun Li
Department of Chemistry, University of Saskatchewan, Saskatoon, Canada S7N 0W0

Sashi V. P. Kumar and Allan L. Stuart
Department of Veterinary Physiological Sciences, University of Saskatchewan, Saskatoon, Canada S7N 0W0

## Guy Tourigny

Department of Chemistry, University of Saskatchewan, Saskatoon, Canada S7N 0W0

Louis T. J. Delbaere

Department of Biochemistry, University of Saskatchewan, Saskatoon,
Canada S7N 0W0
Sagar V. Gupta
Department of Veterinary Physiological Sciences, University of Saskatchewan, Saskatoon, Canada S7N 0W0
(Received 6 July 1993; accepted 2 February 1994)

## Abstract

In the title compound, $\mathrm{C}_{10} \mathrm{H}_{13} \mathrm{~N}_{5} \mathrm{O}_{5}$, the furanose ring adopts a $\mathrm{C}\left(2^{\prime}\right)$-endo envelope conformation $\left({ }^{2} E\right)$, with the glycosyl linkage anti $\left[\chi=219.0(2)^{\circ}\right]$. The
pseudorotational parameters are $P=159.2$ (3) ${ }^{\circ}$ and $\tau_{\mathrm{m}}=34.3(2)^{\circ}$. In the deoxyribose ring, the side chain on $\mathrm{C}\left(5^{\prime}\right)$ is partially disordered and exhibits two distinct conformations, $g^{+}\left[\gamma=58.6(5)^{\circ}\right]$ and $g^{-}[\gamma$ $\left.=-58.2(9)^{\circ}\right]$. The hydroxymethyl side chain at $\mathrm{C}(5)$ is on the same side of the pyrimidine plane as $\mathrm{O}\left(4^{\prime}\right)$ of the furanose ring.

## Comment

5-Hydroxymethyl-2'-deoxyuridine (HMdUrd) is a novel antimetabolite which replaces thymidine in certain lytic bacteriophages (Kallen, Simon \& Mamur, 1962). This naturally occurring nucleoside is a moderate inhibitor of HIV replication in $T$-cell cultures which prolonged the life of mice implanted with Friend Leukemia Virus Complex (Gupta, Stuart, Kumar, De Clercq, Qualtiere, Cozens, Lazdins \& Qualtiere, 1992). HMdUrd has low systemic toxicity and, most interestingly, was devoid of bone-marrow toxicity in mice (Meldrum, Gupta, Lowes \& Paterson, 1985). 3'-Azido-2', $3^{\prime}$-dideoxy-5hydroxymethyluridine (AZHMddUrd) (I) was synthesized to improve potency against HIV. Its crystal structure was determined to establish the relationship between molecular conformation and substrate antiviral activity.

(I)

The glycosidic bond has an anti conformation and the $5^{\prime}-\mathrm{CH}_{2} \mathrm{OH}$ exocyclic side chain is partially disordered, having both $g^{+}$and $g^{-}$conformations. The furanose ring adopts a $\mathrm{C}^{\prime}$-endo envelope conformation $\left({ }^{2} E\right)$ and the 5 -hydroxymethyl group is on the same side of the pyrimidine plane as $\mathrm{O}\left(4^{\prime}\right)$ of the furanose ring. The glycosidic torsion angle $\mathrm{C}(2)-$ $\mathrm{N}(1)-\mathrm{C}\left(1^{\prime}\right)-\mathrm{O}\left(4^{\prime}\right), \quad \chi$, is $219.0(2)^{\circ}$, within the normal range for pyrimidine- $2^{\prime}$-deoxyribonucleosides with an anti conformation. This value is similar to that in molecule $A$ of AZT [ $\chi=234.1$ (4) ${ }^{\circ}$ ] and higher than in molecule $B$ of AZT [ $\chi=188.1$ (2) ${ }^{\circ}$ ] (Dyer, Low, Tollin, Wilson \& Howie, 1988). A pseudorotational analysis of the furanose ring torsion angles with two degrees of freedom for ring puckering (Altona \& Sundaralingam, 1972) gives a phase angle $P=159.2$ (3) ${ }^{\circ}$ and a puckering amplitude $\tau_{\mathrm{m}}=34.3(2)^{\circ}$; the displacement of $\mathrm{C}\left(2^{\prime}\right)$ from
the mean plane through the other four ring atoms is 0.53 (7) $\AA$. As the $5^{\prime}-\mathrm{CH}_{2} \mathrm{OH}$ side chain of the deoxyribose ring in (I) adopts two distinct positions, the subsequent refinement included occupancies for these two sites; these converged at 0.74 and 0.26 for the major and minor sites, respectively. Occupancies were fixed at these values for the final cycle. This disorder, which can be expressed in terms of the torsion angles $\mathrm{C}\left(3^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)-\mathrm{C}\left(5^{\prime}\right)-\mathrm{O}\left(5^{\prime}\right)$ and $\mathrm{C}\left(3^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)-\mathrm{C}\left(5^{\prime}\right)-\mathrm{O}\left(5^{\prime \prime}\right) \quad[\gamma=58.6(5) \quad$ and $-58.2(9)^{\circ}$, respectively], results in either a $g^{+}$or a $g^{-}$conformation. A similar disordered conformation for the hydroxy group at the $\mathrm{C}\left(5^{\prime}\right)$ position of the deoxyribose ring has been reported for 1-(2,3-dideoxy-3-fluoro- $\beta$-D-erythro-pentofuranosyl)-5fluorouracil (Everaert, Peeters, Blaton \& De Ranter, 1992). The pyrimidine ring is slightly non-planar; the largest deviation from the mean plane is $0.05(5) \AA$. The bond angles $\mathrm{C}(2)-\mathrm{N}(1)-\mathrm{C}\left(1^{\prime}\right), \mathrm{C}(6)-\mathrm{N}(1)-$ $\mathrm{C}\left(1^{\prime}\right)$ and $\mathrm{N}(1)-\mathrm{C}\left(1^{\prime}\right)-\mathrm{O}\left(4^{\prime}\right)$ are 118.8 (2), 120.7 (2) and 107.4 (3) $)^{\circ}$, respectively.

There are two intermolecular hydrogen bonds $\left[\mathrm{O}(5,2)-\mathrm{H}(5,2) \cdots \mathrm{O}(4)\left(\frac{3}{2}-x, \quad y-\frac{1}{2}, \quad 1-z\right) ; \quad \mathrm{O}(4) \cdots\right.$ $\mathrm{H}(5,2) \quad 1.79(5), \mathrm{O}(5,2) \cdots \mathrm{O}(4) 2.79(4) \AA$ and $\mathrm{N}(3)-$ $\mathrm{H}(3) \cdots \mathrm{O}(5,2)\left(\frac{1}{2}+x, \frac{1}{2}+y, z\right) ; \mathrm{O}(5,2) \cdots \mathrm{H}(3) 1.95(4)$, $\mathrm{O}(5,2) \cdots \mathrm{N}(3) 2.80(3) \AA]$. Preliminary studies indicate that AZHMddUrd has moderate anti-HIV activity.


Fig. 1. A perspective view of AZHMddUrd (Johnson, 1976). Displacement ellipsoids are drawn at the $50 \%$ probability level.

## Experimental

AZHMddUrd was synthesized by the method of Kumar, Shi, Stuart, Qualtiere \& Gupta (1993). Crystals for X-ray analysis were obtained from a methanol/ethanol/butanol/water solution $(25 \% v / v)$ at 287 K over several weeks.

## Crystal data

$\mathrm{C}_{10} \mathrm{H}_{13} \mathrm{~N}_{5} \mathrm{O}_{5}$
$M_{r}=283.2$
Monoclinic
C2
$a=12.470$ (1) $\AA$
$b=5.6590$
(6) $\AA$
$c=17.700$
(2) $\AA$
$\beta=91.43$ (9) ${ }^{\circ}$
$V=1248.7(2) \AA^{3}$
$Z=4$
$D_{x}=1.507 \mathrm{Mg} \mathrm{m}^{-3}$
$D_{m}=1.523 \mathrm{Mg} \mathrm{m}^{-3}$

## Data collection

| Enraf-Nonius CAD-4 | $R_{\text {int }}=0.0072$ |
| :--- | :--- |
| $\quad$ diffractometer | $\theta_{\max }=75^{\circ}$ |
| $\omega / 2 \theta$ scans | $h=0 \rightarrow 15$ |
| Absorption correction: | $k=0 \rightarrow 7$ |
| none | $l=-22 \rightarrow 22$ |
| 1544 measured reflections | 3 standard reflections |
| 1403 independent reflections | frequency: 83.33 min |
| 1403 observed reflections | intensity variation: <br> insignificant |
|  | ind |

## Refinement

Refinement on $F$
$R=0.044$
$w R=0.060$
$S=4.285$
1403 reflections
224 parameters
$w=1 / \sigma^{2}(F)$
$(\Delta / \sigma)_{\text {max }}=0.0083$
$\Delta \rho_{\text {max }}=0.387$ e $\AA^{-3}$
$\Delta \rho_{\text {min }}=-0.163 \mathrm{e}^{-3}$
$\mathrm{Cu} K \alpha$ radiation
$\lambda=1.5418 \AA$
Cell parameters from 25
reflections
$\theta=13.53-24.98^{\circ}$
$\mu=1.008 \mathrm{~mm}^{-1}$
$T=287(1) \mathrm{K}$
Prism
$0.50 \times 0.30 \times 0.075 \mathrm{~mm}$
Colourless

| $\mathrm{C}\left(4^{\prime}\right)$ | 1 | $0.5869(2)$ | $0.8192(9)$ | $0.8735(2)$ | $0.0473(9)$ |
| :--- | :--- | :--- | :--- | :--- | :--- |
| $\mathrm{O}\left(4^{\prime}\right)$ | 1 | $0.6597(2)$ | $0.6755(7)$ | $0.8321(1)$ | $0.049(7)$ |
| $\mathrm{C}\left(5^{\prime}\right)$ | 1 | $0.4721(3)$ | $0.554(1)$ | $0.8523(2)$ | $0.0660(1)$ |
| $\mathrm{O}\left(5^{\prime}\right)$ | 0.74 | $0.4459(3)$ | $0.7877(9)$ | $0.7774(2)$ | $0.0618(8)$ |
| $\mathrm{O}\left(5^{\prime \prime}\right)$ | 0.26 | $0.404(1)$ | $0.909(4)$ | $0.8929(9)$ | $0.106(5)$ |

Table 2. Bond distances $(\AA)$ and bond angles $\left({ }^{\circ}\right)$

| $\mathrm{N}(1)-\mathrm{C}(2)$ | 1.380 (3) | $\mathrm{C}\left(1^{\prime}\right)-\mathrm{C}\left(2^{\prime}\right) \quad 1$ | 1.517 (6) |
| :---: | :---: | :---: | :---: |
| $\mathrm{N}(1)-\mathrm{C}(6)$ | 1.381 (4) | $\mathrm{C}\left(1^{\prime}\right)-\mathrm{O}\left(4^{\prime}\right) \quad 1$ | 1.418 (4) |
| $\mathrm{N}(1)-\mathrm{C}\left(1^{\prime}\right)$ | 1.469 (4) | $\mathrm{C}\left(2^{\prime}\right)-\mathrm{C}\left(3^{\prime}\right)$ | 1.517 (4) |
| $\mathrm{C}(2)-\mathrm{O}(2)$ | 1.234 (4) | $\mathrm{C}\left(3^{\prime}\right)-\mathrm{N}\left(3^{\prime}, 1\right) \quad 1$ | 1.499 (4) |
| $\mathrm{C}(2)-\mathrm{N}(3)$ | 1.365 (4) | $\mathrm{C}\left(3^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)$ | 1.544 (6) |
| $\mathrm{N}(3)-\mathrm{C}(4)$ | 1.391 (4) | $\mathrm{N}\left(3^{\prime}, 1\right)-\mathrm{N}\left(3^{\prime}, 2\right)$ | 1.190 (5) |
| $\mathrm{C}(4)-\mathrm{O}(4)$ | 1.222 (4) | $\mathrm{N}\left(3^{\prime}, 2\right)-\mathrm{N}\left(3^{\prime}, 3\right) \quad 1$ | 1.110 (7) |
| $\mathrm{C}(4)-\mathrm{C}(5)$ | 1.451 (4) | $\mathrm{C}\left(4^{\prime}\right)-\mathrm{O}\left(4^{\prime}\right) \quad 1$ | 1.434 (5) |
| $\mathrm{C}(5)-\mathrm{C}(5,1)$ | 1.501 (4) | $\mathrm{C}\left(4^{\prime}\right) \mathrm{C}\left(5^{\prime}\right) \quad 1$ | 1.517 (5) |
| $\mathrm{C}(5)-\mathrm{C}(6)$ | 1.334 (4) | $\mathrm{C}\left(5^{\prime}\right)-\mathrm{O}\left(5^{\prime}\right)$ | 1.369 (5) |
| $\mathrm{C}(5,1)-\mathrm{O}(5,2)$ | 1.445 (6) | $\mathrm{C}\left(5^{\prime}\right)-\mathrm{O}\left(5^{\prime \prime}\right)$ | 1.43 (2) |
| $\mathrm{C}(2)-\mathrm{N}(1)-\mathrm{C}(6)$ | 120.4 (2) | $\mathrm{N}(1)-\mathrm{C}\left(1^{\prime}\right)-\mathrm{O}\left(4^{\prime}\right)$ | 107.4 (3) |
| $\mathrm{C}(2)-\mathrm{N}(1)-\mathrm{C}\left(1^{\prime}\right)$ | 118.8 (2) | $\mathrm{C}\left(2^{\prime}\right)-\mathrm{C}\left(1^{\prime}\right)-\mathrm{O}\left(4^{\prime}\right)$ | 106.4 (3) |
| $\mathrm{C}(6)-\mathrm{N} 1)-\mathrm{C}\left(1^{\prime}\right)$ | 120.7 (2) | $\mathrm{C}\left(1^{\prime}\right)-\mathrm{C}\left(2^{\prime}\right)-\mathrm{C}\left(3^{\prime}\right)$ | 101.9 (3) |
| $\mathrm{N}(1)-\mathrm{C}(2)-\mathrm{O}(2)$ | 122.6 (3) | $\mathrm{C}\left(2^{\prime}\right)-\mathrm{C}\left(3^{\prime}\right)-\mathrm{N}\left(3^{\prime}, 1\right)$ | 107.6 (2) |
| $\mathrm{N}(1)-\mathrm{C}(2)-\mathrm{N}(3)$ | 115.0 (2) | $\mathrm{C}\left(2^{\prime}\right)-\mathrm{C}\left(3^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)$ | 103.2 (3) |
| $\mathrm{O}(2)-\mathrm{C}(2)-\mathrm{N}(3)$ | 122.4 (2) | $\mathrm{N}\left(3^{\prime}, 1\right)-\mathrm{C}\left(3^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)$ | 110.8 (3) |
| $\mathrm{C}(2)-\mathrm{N}(3)-\mathrm{C}(4)$ | 127.7 (2) | $\mathrm{C}\left(3^{\prime}\right)-\mathrm{N}\left(3^{\prime}, 1\right)-\mathrm{N}\left(3^{\prime}, 2\right)$ | 115.8 (3) |
| $\mathrm{N}(3)-\mathrm{C}(4)-\mathrm{O}(4)$ | 120.8 (2) | $\mathrm{N}\left(3^{\prime}, 1\right)-\mathrm{N}\left(3^{\prime}, 2\right)-\mathrm{N}\left(3^{\prime}, 3\right)$ | ) 173.6 (5) |
| $\mathrm{N}(3)-\mathrm{C}(4)-\mathrm{C}(5)$ | 113.8 (3) | $\mathrm{C}\left(3^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)-\mathrm{O}\left(4^{\prime}\right)$ | 106.3 (3) |
| $\mathrm{O}(4)-\mathrm{C}(4)-\mathrm{C}(5)$ | 125.4 (3) | $\mathrm{C}\left(3^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)-\mathrm{C}\left(5^{\prime}\right)$ | 114.3 (3) |
| $\mathrm{C}(4)-\mathrm{C}(5)-\mathrm{C}(5,1)$ | 118.0 (3) | $\mathrm{O}\left(4^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)-\mathrm{C}\left(5^{\prime}\right)$ | 110.0 (3) |
| $\mathrm{C}(4)-\mathrm{C}(5)-\mathrm{C}(6)$ | 119.0 (3) | $\mathrm{C}\left(1^{\prime}\right)-\mathrm{O}\left(4^{\prime}\right)-\mathrm{C}\left(4^{\prime}\right)$ | 109.9 (3) |
| $\mathrm{C}(5,1)-\mathrm{C}(5)-\mathrm{C}(6)$ | 123.0 (2) | $\mathrm{C}\left(4^{\prime}\right)-\mathrm{C}\left(5^{\prime}\right)-\mathrm{O}\left(5^{\prime}\right)$ | 114.0 (3) |
| $\mathrm{C}(5)-\mathrm{C}(5,1)-\mathrm{O}(5,2)$ | 112.3 (3) | $\mathrm{C}\left(4^{\prime}\right)-\mathrm{C}\left(5^{\prime}\right)-\mathrm{O}\left(5^{\prime \prime}\right)$ | 107.3 (8) |
| $\mathrm{N}(1)-\mathrm{C}(6)-\mathrm{C}(5)$ | 123.7 (2) | $\mathrm{O}\left(5^{\prime}\right)-\mathrm{C}\left(5^{\prime}\right)-\mathrm{O}\left(5^{\prime \prime}\right)$ | 105.8 (7) |
| $\mathrm{N}(1)-\mathrm{C}\left(1^{\prime}\right)-\mathrm{C}\left(2^{\prime}\right)$ | 114.7 (2) |  |  |

A Bayesian treatment was applied to the data using Xtal3.0 (Hall \& Stewart, 1990). The structure was solved by direct methods with Xtal3.0. All non-H atoms [except $\mathrm{O}\left(5^{\prime}\right)$ and $O\left(5^{\prime \prime}\right)$ ] were found on an $E$ map and refined anisotropically. The positions of most H atoms were located by using difference Fourier maps and refined isotropically, a further two were placed at calculated positions and the final two H atoms were not found. All calculations were performed on a VAX 3100 Model 90 computer at the University of Saskatchewan.

This research was funded by grants from the University of Saskatchewan to SVG and from the Medical Research Council of Canada to SVG (MT-10254) and LTJD (MT-10162).

Table 1. Fractional atomic coordinates and equivalent isotropic displacement parameters $\left(\AA^{2}\right)$

| $U_{\mathrm{eq}}=(1 / 3) \sum_{i} \Sigma_{j} U_{i j} a_{i}^{*} a_{j}^{*} \mathbf{a}_{i} \cdot \mathbf{a}_{j}$ |  |  |  |  |  |
| :--- | :---: | :---: | :---: | :---: | :---: |
|  | Occupancy | $x$ | $y$ | $z$ | $U_{\text {eq }}$ |
| $\mathrm{N}(1)$ | 1 | $0.7557(2)$ | 0.70218 | $0.7214(1)$ | $0.0410(7)$ |
| $\mathrm{C}(2)$ | 1 | $0.8590(2)$ | $0.7095(8)$ | $0.6953(2)$ | $0.0413(8)$ |
| $\mathrm{O}(2)$ | 1 | $0.9312(2)$ | $0.8235(7)$ | $0.7273(1)$ | $0.0555(7)$ |
| $\mathrm{N}(3)$ | 1 | $0.8756(2)$ | $0.5802(8)$ | $0.6315(1)$ | $0.0457(8)$ |
| $\mathrm{C}(4)$ | 1 | $0.7997(2)$ | $0.4592(8)$ | $0.5875(1)$ | $0.0408(8)$ |
| $\mathrm{O}(4)$ | 1 | $0.8256(2)$ | $0.3526(7)$ | $0.5307(1)$ | $0.0526(7)$ |
| $\mathrm{C}(5)$ | 1 | $0.6915(2)$ | $0.4755(7)$ | $0.6154(1)$ | $0.0404(8)$ |
| $\mathrm{C}(5,1)$ | 1 | $0.6025(2)$ | $0.3637(9)$ | $0.5692(2)$ | $0.0500(1)$ |
| $\mathrm{O}(5,2)$ | 1 | $0.5893(2)$ | $0.1162(7)$ | $0.5867(1)$ | $0.0518(7)$ |
| $\mathrm{C}(6)$ | 1 | $0.6749(2)$ | $0.5949(8)$ | $0.6790(1)$ | $0.0424(8)$ |
| $\mathrm{C}\left(1^{\prime}\right)$ | 1 | $0.7323(2)$ | $0.8210(8)$ | $0.7929(1)$ | $0.0416(8)$ |
| $\mathrm{C}\left(2^{\prime}\right)$ | 1 | $0.6784(2)$ | $1.0601(8)$ | $0.7841(2)$ | $0.0459(9)$ |
| $\mathrm{C}\left(3^{\prime}\right)$ | 1 | $0.6167(2)$ | $1.0783(8)$ | $0.8566(2)$ | $0.0471(9)$ |
| $\mathrm{N}\left(3^{\prime}, 1\right)$ | 1 | $0.6918(2)$ | $1.1742(9)$ | $0.9166(2)$ | $0.0610(1)$ |
| $\mathrm{N}\left(3^{\prime}, 2\right)$ | 1 | $0.6516(3)$ | $1.233(1)$ | $0.9739(2)$ | $0.0740(1)$ |
| $\mathrm{N}\left(3^{\prime}, 3\right)$ | 1 | $0.6232(4)$ | $1.293(2)$ | $1.0296(3)$ | $0.178(5)$ |

Lists of structure factors, anisotropic displacement parameters and H -atom coordinates have been deposited with the IUCr (Reference: ST1088). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

## References

Altona, C. \& Sundaralingam, M. (1972). J. Am. Chem. Soc. 94, 8205-8212.
Dyer, I., Low, J. N., Tollin, P., Wilson, H. R. \& Howie, R. A. (1988). Acta Cryst. C44, 767-769.

Everaert, D. H., Peeters, O. M., Blaton, N. M. \& De Ranter, C. J. (1992). Acta Cryst. C48, 590-592.

Gupta, V. S., Stuart, A. L., Kumar, S. V. P., De Clercq, E., Qualtiere, J., Cozens, R. M., Lazdins, J. K. \& Qualtiere, L. F. (1992). Proceedings of the 5th International Conference on Antiviral Research, Abstract 64. Vancouver, BC, Canada.

Hall, S. R. \& Stewart, J. M. (1990). Editors. Xtal 3.0 Reference Manual. Univs. of Western Australia, Australia, and Maryland, USA.
Johnson, C. K. (1976). ORTEPII. Report ORNL-5138. Oak Ridge National Laboratory, Tennessee, USA.
Kallen, R. G., Simon, M. \& Mamur, J. (1962). J. Mol. Biol. 5, 248-250.
Kumar, S. V. P., Shi, R., Stuart, A. L., Qualtiere, L. F. \& Gupta, V. S. (1993). J. Med. Chem. In preparation.

Larson, A. C. (1970). Crystallographic Computing, edited by F. R. Ahmed, S. R. Hall \& C. P. Huber, pp. 291-294. Copenhagen: Munksgaard.
Meldrum, J. B., Gupta, V. S., Lowes, N. R. \& Paterson, A. R. P. (1985). Toxicol. Appl. Pharmacol. 79, 423-435.

Acta Cryst. (1994). C50, 1629-1631

# DCMCIT, an Analogue of the Antitumour Drugs Mitozolomide and Temozolomide 

P. R. Lowe and C. H. Schwalbe<br>Pharmaceutical Sciences Institute, Aston University, Aston Triangle, Birmingham B4 7ET, England

(Received 10 November 1993; accepted 7 March 1994)


#### Abstract

The crystal structure of 3 -(2-chloroethyl)- $\mathrm{N}, \mathrm{N}$-di-methyl-4-oxo-3,4-dihydroimidazo[5,1-d]-1,2,3,5- tetrazine-8-carboxamide, (1), $\mathrm{C}_{9} \mathrm{H}_{11} \mathrm{ClN}_{6} \mathrm{O}_{2}$, an analogue of the novel bicyclic antitumour agents mitozolomide (2) and temozolomide (3), has been determined at 290 K . Although, as in structures (2) and (3), the imidazotetrazinone ring system is essentially planar, the substitution of the $-\mathrm{CONH}_{2}$ group at C 8 by a $-\mathrm{CON}\left(\mathrm{CH}_{3}\right)_{2}$ group in (1) negates the possibility of forming an intramolecular hydrogen bond at either N7 or N1 and thus allows rotation of this group about the $\mathrm{C} 8-\mathrm{C} 81$ bond by ca $45^{\circ}$.


## Comment

Structure-activity studies on 8 -substituted imidazotetrazinones show very good antitumour activity for both unsubstituted and a range of N-monosubstituted carboxamides (Lunt et al., 1987). The proposed mode of action is that of a prodrug for two cytotoxic alkylating species: MCTIC (4) for analogues of mitozolomide and MTIC (5) for analogues of temozolomide. The model proposes that this is effected by ring opening at the weak C4-N5 bond following nucleophilic attack at the C4 atom by water molecules in the major groove of DNA (Clark, Stevens, Sansom \& Schwalbe, 1990). It is further
postulated that the carboxamide substitutent may play an important role in DNA sequence recognition (Lowe, Sansom, Schwalbe, Stevens \& Clark, 1992).

(1) $R_{1}=\left(\mathrm{CH}_{2}\right)_{2} \mathrm{Cl}, R_{2}=\mathrm{CON}\left(\mathrm{CH}_{3}\right)_{2}$ DCMCIT
(2) $R_{1}=\left(\mathrm{CH}_{2}\right)_{2} \mathrm{Cl}, R_{2}=\mathrm{CONH}_{2}$ Mitozolomide
(3) $R_{1}=\mathrm{CH}_{3}, R_{2}=\mathrm{CONH}_{2}$ Temozolomide


The fact that the title compound differs from (2) only in that it is N -disubstituted, and yet has very impaired activity, points to the importance of the nature of the carboxamide substituent; it is proposed that DCMCIT has to undergo metabolic demethylation to become active (Lowe, Sansom, Schwalbe, Stevens \& Clark, 1992).
Although, in general, the bond lengths in the planar bicyclic ring system are similar in compounds (1), (2) and (3), a difference does occur in the $\mathrm{N} 1-\mathrm{N} 2, \mathrm{~N} 1-\mathrm{C} 8 A$ and $\mathrm{C} 8-\mathrm{C} 8 A$ bond lengths which are shorter, longer and shorter, respectively, by greater than $3 \sigma$ in structure (1) than in structures (2) and (3), suggesting considerably less conjugation (Lowe, Schwalbe \& Stevens, 1985; Lowe, Sansom, Schwalbe, Stevens \& Clark, 1992). While it is tempting to attribute this largely to the coplanar nature of the carboxamide group and ring system in structures (2) and (3) compared with the observed twist in structure (1) $\left[\mathrm{C} 8 A-\mathrm{C} 8-\mathrm{C} 81-\mathrm{O} 8246.1\right.$ (4) $\left.{ }^{\circ}\right]$ which reduces the conjugative effect between them, it is not substantiated by the C8-C81 bond length which shows little variation among the three compounds.

The C81-N82 bond length of 1.334 (3) $\AA$ suggests considerable double-bond character, which is consistent with $s p^{2}$ hybridization of the amide N atom shown by the closeness to $360^{\circ}$ of the sum of the bond angles around the N 82 atom [359.8(4) ${ }^{\circ}$ ]. As such, conjugation appears to be restricted to the ring system and the carboxamide group separated by the rotation about the $\mathrm{C} 8-\mathrm{C} 81$ bond.

Since the title compound (1) is N -disubstituted, no strong hydrogen bonds exist, as demonstrated by the relatively low melting point of 389 K . However, there is a somewhat weaker interaction, namely


[^0]:    Lists of structure factors, anisotropic displacement parameters, H atom coordinates and complete geometry have been deposited with the IUCr (Reference: KA1067). Copies may be obtained through The Managing Editor, International Union of Crystallography, 5 Abbey Square, Chester CH1 2HU, England.

